ATC Group: A07EC04 Balsalazide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07EC04 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3
Intestinal antiinflammatory agents
4
Aminosalicylic acid and similar agents
5
A07EC04
Balsalazide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
6.75 g

Active ingredients in A07EC04

Active Ingredient
Description

Balsalazide consists of mesalazine linked to a carrier molecule (4-aminobenzoyl-ß-alanine) via an azo bond. Bacterial azo-reduction releases mesalazine as an active metabolite in the colon. Mesalazine is an intestinal anti-inflammatory agent acting locally on the colonic mucosa. Its precise mechanism of action is unknown.

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Medicines in this ATC group

Australia (AU)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.